Who Supplies Enalapril to India from MALAYSIA

Importing finished pharmaceutical formulations containing Enalapril into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. Applications for registration must be submitted in Form 40, accompanied by documents such as the plant master file, manufacturing license from the country of origin, Good Manufacturing Practice (GMP) certificate, Certificate of Pharmaceutical Products (CPP), drug substance information, finished formulation details, clinical documentation, and packaging and labeling information. The registration is valid for three years, after which a commercial import license in Form 8 or Form 8A can be obtained.

Imported Enalapril formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required, with each batch accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV, is necessary to ensure product efficacy and safety in India's climate. Port inspections by customs drug inspectors are conducted to verify compliance with regulatory standards.

Between 2024 and 2026, the CDSCO has implemented regulatory updates affecting the import of finished pharmaceutical formulations. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Malaysia have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), thereby streamlining the import process for Malaysian pharmaceutical products.

India imports finished Enalapril formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for manufacturing certain Enalapril formulations is limited, leading to a dependency on imports to fulfill market needs. The market size for Enalapril formulations in India is substantial, with a growing patient population requiring antihypertensive treatments.

The Basic Customs Duty (BCD) for Enalapril formulations under HS Code 30049071 is 10%. With Malaysia's preferential duty rates under the ASEAN-India Free Trade Area (AIFTA) agreement, the duty is reduced to 5%. Additional taxes include the Social Welfare Surcharge (SWS), Integrated Goods and Services Tax (IGST), and other applicable cess. Exemption notifications may apply under specific conditions, affecting the total landed duty percentage.

India sources Enalapril formulations from Malaysia due to competitive advantages such as patents, specialized dosage forms, and high-quality manufacturing standards. Malaysian suppliers offer formulations that may not be available from other origins, providing a unique value proposition. Other suppliers, including China, Germany, and the United States, also contribute to India's Enalapril import market, but Malaysia's share remains significant due to these advantages.

India imports Enalapril formulations from Malaysia due to strategic reasons such as access to patented formulations, specialized dosage forms, and technology-licensed products. Specific formulations supplied by Malaysia, which are not manufactured domestically, fulfill critical market needs.

When compared to other origins like China, the European Union, and the United States, Malaysia offers competitive pricing, high-quality manufacturing, and regulatory compliance. These factors make Malaysia a preferred source for Enalapril formulations, providing a unique advantage over other suppliers.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but it is advisable to monitor these risks proactively to ensure a stable supply chain.

1. 1Engage in dual-sourcing strategies to mitigate supply chain risks.
2. 2Implement comprehensive inventory planning to manage demand fluctuations.
3. 3Establish favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Negotiate Minimum Order Quantities (MOQs) that align with market demand and storage capabilities.
5. 5Conduct thorough supplier qualification processes to ensure compliance with regulatory standards and quality expectations.

1. 1Obtain a Directorate General of Foreign Trade (DGFT) Importer Exporter Code (IEC).
2. 2Register the product with CDSCO using Form 40.
3. 3Secure a Drug Import License.
4. 4Obtain a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare.
5. 5Engage a licensed customs broker for import clearance.
6. 6Seek an advance ruling for HS Code 30049071 to confirm classification and applicable duties.

1. 1Certificate of Analysis (CoA).
2. 2Certificate of Pharmaceutical Products (CPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF).
5. 5Stability data adhering to ICH Zone IVa/IVb guidelines.
6. 6Free Sale Certificate.
7. 7Manufacturer's authorization letter.

Upon arrival, customs drug inspectors collect samples of imported Enalapril formulations for mandatory batch testing. The testing process includes verifying compliance with Indian Pharmacopoeia standards and assessing stability data. If a batch fails to meet the required standards, it may be rejected, leading to potential delays and additional costs. Common quality issues from Malaysia have been minimal, but vigilance is essential to maintain product integrity.

1. 1Renew CDSCO registration annually.
2. 2Schedule periodic audits of Malaysian manufacturing facilities.
3. 3Implement change control procedures to manage product modifications.
4. 4Establish a pharmacovigilance system for post-import monitoring.
5. 5Maintain detailed import records as per the Drugs and Cosmetics Act.